The Bulletin
Men's Weekly


.

Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese encephalitis across Asia

  • Written by The Bulletin

New commercialisation agreement builds on existing partnership with Zuellig Pharma

SINGAPORE - Media OutReach Newswire - 16 January 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced its commercialisation partnership with pharmaceutical company Substipharm Biologics, to expand access of the IMOJEV® Japanese encephalitis vaccine across nine markets in Asia, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.

Read more: Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese...